Table 1. Median frequency of mutated genes found in PM-CRC patient samples in more than one study.

Mutated genes	Median mutation, frequency (%) [min–max]	Median # samples analyzed [min–max]	References
TP53	54 [33–75]	54 [51–57]	(19,20)
RAS, not specified*	58	150	(21)
KRAS	45 [20–57]	52 [11–397]	(19,20,22-31)
APC	44 [31–57]	56 [51–61]	(19,20)
SMAD4	22 [15–29]	56 [51–60]	(19,20)
BRAF	15 [6–40]	59 [11–378]	(19,20,22-25,27-30,32,33)
PIK3CA	13 [9–14]	58 [51–103]	(19,20,23)
FBXW7	9 [8–9]	55 [51–59]	(19,20)
GNAS	4 [2–5]	55 [51–58]	(19,20)
NRAS	4 [2–5]	96 [47–378]	(19,22)
PTEN	4 [2–6]	55 [51–58]	(19,20)
JAK3	4 [2–6]	55 [51–59]	(19,20)
AKT1	3 [2–4]	55 [51–59]	(19,20)
STK11	3 [2–4]	54 [51–56]	(19,20)
CTNNB1	3 [2–3]	56 [51–61]	(19,20)
HNF1A	3 [2–4]	51 [50–51]	(19,20)
SMO	3 [2–4]	54 [51–57]	(19,20)
ERBB2	2 [2–2]	55 [51–58]	(19,20)

Data from (19) was provided through personal communication. *, frequency of KRAS and NRAS mutations separately were not provided. PM-CRC, peritoneal metastases from colorectal cancer.